Deferred Tax Assets, Valuation Allowance of Syndax Pharmaceuticals Inc from 31 Dec 2015 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Syndax Pharmaceuticals Inc quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2015 to 31 Dec 2025.
  • Syndax Pharmaceuticals Inc Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2025 was $339,706,000, a 31% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Syndax Pharmaceuticals Inc Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $339,706,000 +$81,068,000 +31% 31 Dec 2025 10-K 26 Feb 2026 2025 FY
Q4 2024 $258,638,000 +$52,681,000 +26% 31 Dec 2024 10-K 26 Feb 2026 2025 FY
Q4 2023 $205,957,000 +$72,876,000 +55% 31 Dec 2023 10-K 03 Mar 2025 2024 FY
Q4 2022 $133,081,000 +$35,931,000 +37% 31 Dec 2022 10-K 27 Feb 2024 2023 FY
Q4 2021 $97,150,000 -$4,778,000 -4.7% 31 Dec 2021 10-K 28 Feb 2023 2022 FY
Q4 2020 $101,928,000 +$17,512,000 +21% 31 Dec 2020 10-K 01 Mar 2022 2021 FY
Q4 2019 $84,416,000 +$12,765,000 +18% 31 Dec 2019 10-K 12 Mar 2021 2020 FY
Q4 2018 $71,651,000 +$17,204,000 +32% 31 Dec 2018 10-K 05 Mar 2020 2019 FY
Q4 2017 $54,447,000 -$5,876,000 -9.7% 31 Dec 2017 10-K 07 Mar 2019 2018 FY
Q4 2016 $60,323,000 +$12,964,000 +27% 31 Dec 2016 10-K 08 Mar 2018 2017 FY
Q4 2015 $47,359,000 31 Dec 2015 10-K 14 Mar 2017 2016 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.